XpresSpa Group, whose sales were $48.5 million last year, has signed a contract with JFK International Air Terminal LLC—the private operator of Terminal 4— to provide diagnostic tests for Covid-19, initially to airport and airline staff.
The pilot concept paves the way for the company to enter the medical sphere and widen its reach within the health and wellness segment in which it has been a player for 15 years.
Doug Satzman, CEO of XpresSpa Group since February 2019, tells me: “Initially we thought this might be a short-term project—perhaps six months or so to help alleviate the crisis. But we now believe it will evolve into a separate line of business.”
In Terminal 4, a modular facility has been developed pre-security with nine separate rooms that can administer over 500 tests per day. They will be a combination of nasal swabs and blood antibody tests for off-premise analysis. Future airport test spaces could be located within existing XpresSpa retail areas, which are mostly airside, or in a pre-security area like the pilot. In total, XpresSpa has 46 locations at 23 airports in the U.S. to choose from.
The Nasdaq-listed health and wellness company says it is working with the Port Authority of New York and New Jersey—which runs John F. Kennedy Airport as well as Newark and LaGuardia—to expand testing sites. Once confirmed, they could roll out this summer.
The company has the advantage of being in all the biggest U.S. hub airports which are also key point-of-entry cities. They include New York, Los Angeles, San Francisco, Chicago, Miami, Atlanta, and Washington. XpresSpa’s employees are already TSA security approved so they can be trained and deployed quickly.
A new brand and subsidiary for Covid-19 testing
XpresSpa has created a new brand, XpresCheck, for its Covid-19 screenings, which will be offered to airline employees, contractors and workers, airport concessionaires and their staff, TSA officers, and U.S. Customs and Border Protection agents.
XpresCheck is part of a specially-created subsidiary called XpresTest. In April, the company appointed Lewis Lipsey MD as chief medical director of XpresTest to help design Covid-19 protocols, as well as to train employees on testing procedures. Prior to taking the job, Dr. Lipsey was an attending physician at several hospitals in New York City, including The Mount Sinai, Mount Sinai Beth Israel, and Lenox Hill.
Last year, XpresSpa Group held 60% of the U.S. airport spa services market, making it more than three times bigger than its nearest rival, Be Relax. The company’s 51 locations in 25 airports globally include three in Amsterdam Schiphol Airport in the Netherlands, and two in Dubai International Airport in the United Arab Emirates.
https://www.forbes.com/sites/kevinrozario/2020/05/27/xpresspa-pivots-to-coronavirus-testing-at-new-yorks-john-f-kennedy-airport/#439ba9f944a4
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.